Poseida Therapeutics appoints Harry J. Leonhardt, Esq. as General Counsel

SAN DIEGO, July 16, 2020 /PRNewswire/ –Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced biotech veteran Harry J. Leonhardt, Esq. has joined the company as General Counsel and Chief Compliance Officer.